ABBVAbbVie

Health care · Pharmaceuticals · NYSE

AbbVie operates as a single global business segment dedicated to the research and development, manufacturing, commercialization and sale of innovative medicines and therapies. 10-K, Item 1

Employees: 57,000
Headquarters: North Chicago, IL
Next results: around Jan 6, 2027

Compare with peers → Embed

RevenueFY2016–25 $61.2B+8.6% Highest in 10 years 10-K FY2025 · XBRL Net incomeFY2016–25 $4.2B−1.2% FY2024: $4.3B 10-K FY2025 · XBRL Free cash flowFY2016–25 $17.8B−0.1% FY2024: $17.8B 10-K FY2025 · XBRL Operating marginFY2016–25 24.6%+8.4 pts 36.4% in FY2016 10-K FY2025 · XBRL

What changed

10-K filed Feb 20, 2026 against Feb 14, 2025

Area	What changed	Source
Risk factors	8 new paragraphs, nothing like them in the previous 10-K	10-K Item 1A
Material impairment (8-K item 2.06)	8-K item 2.06 (material impairments) filed 2025-01-10	10-K · XBRL
Accounting checks	10 other checks clear, 1 worth a look	10-K · XBRL
Insiders	No open-market buys in the last 90 days	Form 4
Filings	4 in the last 30 days	EDGAR

Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.

What's new, in their words

10-K filed Feb 20, 2026

Paragraphs in Risk Factors that were not in the 10-K filed 2025-02-14. Quoted as filed.

In addition to the pricing mechanisms established under the IRA, governments and other payers may pursue or implement additional approaches intended to reduce pharmaceutical costs, including arrangements or frameworks that reference international prices, most-favored-nation (MFN) concepts, or other comparative pricing methodologies.…
10-K, Item 1A

All 8 new paragraphs →

Accounting checks

latest 10-K

10 of 11 clear 1 worth a look. Checks, not verdicts.

!
Material impairment (8-K item 2.06)8-K item 2.06 (material impairments) filed 2025-01-10
✓
Receivables +15.3% vs revenue +8.6% (+6.7 pts)
✓
Cash from operations $19.0B vs net income $4.2B (FY ending 2025-12-31)
✓
Inventory +18.4% vs revenue +8.6% (+9.8 pts)
✓
Same auditor in both 10-Ks: Ernst & Young LLP
✓
No statement of substantial doubt about going concern
✓
No 8-K item 4.02 in the last 2 years
✓
No NT 10-K or NT 10-Q in the last 2 years
✓
No longer listed: Valuation of contingent consideration. Same as last year: Sales rebate accruals for Medicaid, Medicare and managed care programs
✓
No sentence in the 10-K concludes that controls were not effective because of a material weakness
✓
No 8-K item 1.03 in the last 2 years

How each check works, with sources →

In the last 30 days

All filings →

Nov 3, 202610-Q Quarterly report (10-Q) period ended Sep 30, 2026
Nov 2, 20268-K Director or officer change 8-K item 5.02
Oct 30, 20268-K Quarterly results 8-K item 2.02
Oct 15, 20268-K Director or officer change 8-K item 5.02

Get an email when this changes: new risk paragraphs, accounting items, insider purchases, a new 10-K or 10-Q. RSS feed

Work on ABBV in a spreadsheet: Excel workbook (a sheet per section, ten years by column, charts, links to the filings) · CSV. For a Google Sheet that stays up to date, paste =IMPORTDATA("https://tickdelta.com/company/ABBV/export.csv") into a cell.